Trial reportMultiple sclerosis and related disorders2025
Effects of vascular disease risk factors on brain metabolism in multiple sclerosis.
Trial report in Multiple sclerosis and related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02424825 (A Low-fat, Plant-based Cooking Course for Patients With Multiple Sclerosis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Low-fat, Plant-based Cooking Course for Patients With Multiple Sclerosis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundVascular disease risk factors (VDRF) seemingly contribute to disability progression in people with multiple sclerosis (pwMS). One possible mechanism is impaired brain energy metabolism, quantifiable by measuring adenosine triphosphate (ATP) using magnetic resonance spectroscopic imaging (MRSI).
objectiveTo determine how VDRF affect brain ATP in pwMS.
methodsWe performed a 3-year longitudinal prospective study comparing pwMS with and without VDRF (VDRF+ and VDRF-). We collected 7T MRI and MRSI every 12 months, and clinical data every 6 months. The primary outcome was brain ATP. Using a modified Framingham Risk Scale (FRS) and waist circumference (WC) as a measure of abdominal adiposity, we performed a secondary analysis to understand specific vascular disease risk factor contributions.
resultsOf the 60 participants recruited, 52 completed sufficient sessions for analysis. VDRF+ had lower ATP at baseline compared to VDRF- (0.296 vs 0.316). This difference was largely unchanged over 3 years. Larger WC associated with lower ATP at baseline (partial r(47)=-0.38). The association between ATP and FRS was weak (partial r(47)=0.10). DISCUSSION: While VDRF associate with impaired brain metabolism in pwMS, appropriate control of risk factors may reduce the risk of worsened metabolic dysfunction over time. Notably, abdominal adiposity negatively affects brain energy metabolism. CLINICAL TRIAL NUMBER: NCT02424825.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.